A prospective randomised study in limited disease small cell carcinoma-- @entity632 and XXXX plus either @entity786 or @entity2879 .

@entity1 @entity632 @entity137 @entity296 @entity786 @entity2879 @entity1891 @entity151 @entity3895 @entity1210
A prospective randomised study was undertaken in @entity1 with @entity151 ( @entity151 ), which compared @entity632 , 50 mg/m2, and @entity1891 , 2 mg i.v. (intravenously) on day 1, with either @entity786 , 800 mg/m2 on day 1 ( @entity3895 ) or @entity2879 , 60 mg/m2 i.v. on day 1 and 120 mg/m2 orally on days 2-5 (AVE). Responding @entity1 were to receive six cycles of chemotherapy at 3 weekly intervals followed after 2 weeks by mediastinal irradiation. Response rates and @entity137 were evaluated by the chi square or Fisher's exact test and survival by the logrank test. 81 @entity1 were entered into the study, 38 of whom received @entity3895 and 43 received AVE. In the @entity1 treated with @entity3895 and AVE, the overall response rate was 61% (confidence limit (CL), 45-71%) and 74% (CL, 61-87%) respectively, the complete response rate was 32% (CL, 17-47%) and 51% (CL, 36-66%), respectively (P = 0.07) and the median survival was 12 and 14.5 months, respectively (P = 0.15). In the @entity1 treated with @entity3895 and AVE, the incidence of grade 3 and 4 @entity1210 was 29% (CL, 15-43%) and 9% (CL, 0-18%), respectively (P = 0.025). No @entity1 developed @entity632 @entity296 . These findings support the role of @entity2879 in first line chemotherapy for @entity151 . AVE is among the more efficacious regimens for @entity151 and also has a relatively low @entity137 .
